#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glycogen storage disease type V Choroidal dystrophy Acromegaly Human papilloma virus immunisation Glomerulonephritis acute Testicular leiomyosarcoma Hypoxic-ischaemic encephalopathy Ventricular fibrillation Marfan's syndrome Small cell lung cancer extensive stage Drug eruption Malignant oligodendroglioma Epidermolysis bullosa Idiopathic inflammatory myopathy Hepatic cirrhosis More trials…

    Learn about Rare Diseases

    Pulmonary sarcoidosis – Life with Disease Prader-Willi syndrome – Basic Information Idiopathic inflammatory myopathy Mantle cell lymphoma stage III Adrenocortical carcinoma – Basic Information Marginal zone lymphoma refractory – Trials in Disease Splenic marginal zone lymphoma – Treatment IgA nephropathy – Diagnostics Primary mediastinal large B-cell lymphoma – Diagnostics Turner’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    TRIMIPRAMINE MALEATE Efgartigimod Alfa Levocabastine Hydrochloride Verapamil Zinc Acetate Dihydrate Alpha-Tocopherol Empasiprubart Human Albumin Solution Imsidolimab Sodium Hypochlorite 4-IODOPHENYLALANINE I-131 Glycerol Calcium Folinate Mirabegron Monalizumab Benzylpenicillin Imidapril Hydrochloride Goserelin Perflutren ULIXERTINIB More therapies…

    Learn about Your Condition

    Prinzmetal angina Chondrosarcoma Neuropathic arthropathy Mucous membrane pemphigoid Breast conserving surgery Stress Skin bacterial infection Iron overload Supranuclear palsy Prader-Willi syndrome Tubulointerstitial nephritis Respiratory tract infection Inclusion body myositis Interstitial lung disease Breast cancer stage I More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cabinet Medical Individual Lauderma

Cabinet Medical Individual Lauderma

Bulevardul Chimiei nr. 4, Iasi, 700401, Romania

Want to learn more about this study or check if you can participate? Contact us.

  • Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Deucravacitinib
    • Ustekinumab
    Belgium Bulgaria Czechia Denmark France Germany +6

  • Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Envudeucitinib
    Austria Belgium Bulgaria Czechia Estonia France +7

  • Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Apremilast
    • Envudeucitinib
    Austria Estonia France Germany Hungary Latvia +3

  • Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

    Not recruiting

    3 1
    Investigated Diseases:
    • Cutaneous lupus erythematosus
    Investigated Drugs:
    • Anifrolumab
    Austria Bulgaria Denmark France Germany Greece +7

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!